Previous
Previous

An Ethical Allocation Scheme for Scarce Gene Therapies in Sickle Cell Disease andTransfusion-Dependent β-Thalassemia

Next
Next

Clinical and Economic Burden of Managing Patientswith Sickle Cell Disease Receiving Frequent Red BloodCell Transfusions in the United States